APA

Klisovic R. B., Blum W., Liu Z., Xie Z., Kefauver C., Huynh L., Zwiebel J. A., Devine S. M., Byrd J. C., Grever M. R., Chan K. K. & Marcucci G. (20150715). Phase I study of GTI-2040, a ribonucleotide reductase antisense, with high dose cytarabine in patients with relapsed/refractory acute myeloid leukemia. : Leukemia & lymphoma.

Chicago

Klisovic Rebecca B, Blum William, Liu Zhongfa, Xie Zhiliang, Kefauver Cheryl, Huynh Lenguyen, Zwiebel James A, Devine Steven M, Byrd John C, Grever Michael R, Chan Kenneth K and Marcucci Guido. 20150715. Phase I study of GTI-2040, a ribonucleotide reductase antisense, with high dose cytarabine in patients with relapsed/refractory acute myeloid leukemia. : Leukemia & lymphoma.

Harvard

Klisovic R. B., Blum W., Liu Z., Xie Z., Kefauver C., Huynh L., Zwiebel J. A., Devine S. M., Byrd J. C., Grever M. R., Chan K. K. and Marcucci G. (20150715). Phase I study of GTI-2040, a ribonucleotide reductase antisense, with high dose cytarabine in patients with relapsed/refractory acute myeloid leukemia. : Leukemia & lymphoma.

MLA

Klisovic Rebecca B, Blum William, Liu Zhongfa, Xie Zhiliang, Kefauver Cheryl, Huynh Lenguyen, Zwiebel James A, Devine Steven M, Byrd John C, Grever Michael R, Chan Kenneth K and Marcucci Guido. Phase I study of GTI-2040, a ribonucleotide reductase antisense, with high dose cytarabine in patients with relapsed/refractory acute myeloid leukemia. : Leukemia & lymphoma. 20150715.